Updated Analysis of an Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

被引：2
|
作者：
Coyle, Luke
Morley, Nicholas J.
Rambaldi, Alessandro
Mason, Kylie D.
Verhoef, Gregor
Furness, Caroline
Desai, Rajendra
Mergen, Noemi
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141117
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomab
    Naegele, Virginie
    Zugmaier, Gerhard
    Goebeler, Maria-Elisabeth
    Viardot, Andreas
    Bargou, Ralf
    Kufer, Peter
    Klinger, Matthias
    EXPERIMENTAL HEMATOLOGY, 2021, 100 : 32 - 36
  • [42] A Phase 2 Study of Weekly Temsirolimus and Bortezomib for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Wisconsin Oncology Network Study
    Fenske, Timothy S.
    Shah, Namrata M.
    Kim, Kyung Mann
    Saha, Sandeep
    Zhang, Chong
    Baim, Arielle E.
    Farnen, John P.
    Onitilo, Adedayo A.
    Blank, Jules H.
    Ahuja, Harish
    Wassenaar, Tim
    Qamar, Rubina
    Mansky, Patrick
    Traynor, Anne M.
    Mattison, Ryan J.
    Kahl, Brad S.
    CANCER, 2015, 121 (19) : 3465 - 3471
  • [43] An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma
    Morschhauser, Franck
    Salles, Gilles
    Le Gouill, Steven
    Tilly, Herve
    Thieblemont, Catherine
    Bouabdallah, Krimo
    Fabiani, Bettina
    Menard, Cedric
    Tarte, Karin
    Cartron, Guillaume
    Houot, Roch
    BLOOD, 2018, 132 (14) : 1486 - 1494
  • [44] BISPECIFIC T-CELL ENGAGER (BITE®) ANTIBODY BLINATUMOMAB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): AN OPEN-LABEL PHASE 2 STUDY
    Viardot, A.
    Goebeler, M.
    Pfreundschuh, M.
    Adrian, N.
    Libicher, M.
    Hess, G.
    Zettl, F.
    Neumann, S.
    Degenhard, E.
    Stieglmaier, J.
    Zhang, A.
    Nagorsen, D.
    Bargou, R. C.
    HAEMATOLOGICA, 2014, 99 : 154 - 154
  • [45] Rates and Durability of Response to Salvage Radiation Therapy Among Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma
    Tseng, Y. D.
    Chen, Y.
    Catalano, P.
    Mauch, P. M.
    Ng, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S60 - S60
  • [46] Impact of type of salvage therapy (ST) and response to bridging therapy (BT) on CAR-T therapy outcomes for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
    Khurana, Arushi
    Al Saleh, Abdullah S.
    Gandhi, Sangeetha
    Tuan Truong
    Brandes, Eva
    Estby, Breanna
    Lange, Gina
    Villasboas, Jose Caetano
    Paludo, Jonas
    Bennani, N. Nora
    Ansell, Stephen M.
    Johnston, Patrick B.
    Lin, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Rates and Durability of Response to Salvage Radiation Therapy Among Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma
    Tseng, Yolanda D.
    Chen, Yu-Hui
    Catalano, Paul J.
    Ng, Andrea
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 91 (01): : 223 - 231
  • [48] Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
    Sehgal, Alison
    Hoda, Daanish
    Riedell, Peter A.
    Ghosh, Nilanjan
    Hamadani, Mehdi
    Hildebrandt, Gerhard C.
    Godwin, John E.
    Reagan, Patrick M.
    Wagner-Johnston, Nina
    Essell, James
    Nath, Rajneesh
    Solomon, Scott R.
    Champion, Rebecca
    Licitra, Edward
    Fanning, Suzanne
    Gupta, Neel
    Dubowy, Ronald
    D'Andrea, Aleco
    Wang, Lei
    Ogasawara, Ken
    Thorpe, Jerill
    Gordon, Leo, I
    LANCET ONCOLOGY, 2022, 23 (08): : 1066 - 1077
  • [49] An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
    Witzig, T. E.
    Vose, J. M.
    Zinzani, P. L.
    Reeder, C. B.
    Buckstein, R.
    Polikoff, J. A.
    Bouabdallah, R.
    Haioun, C.
    Tilly, H.
    Guo, P.
    Pietronigro, D.
    Ervin-Haynes, A. L.
    Czuczman, M. S.
    ANNALS OF ONCOLOGY, 2011, 22 (07) : 1622 - 1627
  • [50] Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    Heyman, Benjamin
    Rizzieri, David
    Adams, David J.
    De Castro, Carlos
    Diehl, Louis
    Li, Zhiguo
    Moore, Joseph
    Beaven, Anne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (10): : 679 - 686
12345